{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:14:01Z","timestamp":1764785641732,"version":"3.41.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Bencycloquidium bromide (BCQB) is a novel synthesized quaternary ammonium salt compound based on the classic anticholinergic drug ipratropium bromide. This study was to compare the efficacy of BCQB and montelukast (MNT) combination therapy to that of MNT monotherapy in the treatment of moderate to severe allergic rhinitis ((M\/S)AR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This study enrolled enrolled 300 patients with (M\/S)AR. The participants were randomized to receive BCQB (180\u2005\u03bcg each time, qid) plus MNT (10\u2005mg qn) (BCQB\u2005+\u2005MNT group) or MNT alone (10\u2005mg qn) for 4 weeks. The visual analog scale (VAS) for rhinorrhea, sneezing, nasal congestion, itching, and the rhinoconjunctivitis quality of life questionnaire (RQLQ) were assessed before and at the end of treatments. Adverse events were recorded in detail.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>FAS analysis was performed on a total of 133 and 134 patients, in the BCQB\u2005+\u2005MNT group and in MNT group, respectively. The baseline information was comparable. Both treatments significantly reduced the score of total VAS and 4 main VAS symptoms compared to baseline. However, the BCQB\u2005+\u2005MNT group exhibited significantly greater decrease in scores for rhinorrhea and nasal congestion compared to MNT alone. After 2 weeks of treatment, the BCQB\u2005+\u2005MNT group showed significantly larger decrease in the RQLQ score in terms of daily living, nonnasal and ocular symptoms, behavioral problems, nasal symptoms, and ocular symptoms compared to MNT alone. At the end of the trial, both treatments significantly reduced the total RQLQ score from baseline; however, the BCQB\u2005+\u2005MNT group showed significant decrease in scores compared to MNT alone. Mild and transient adverse events were recorded, which were similar between the 2 groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The combination of BCQB and MNT had a greater overall effect, compared to MNT monotherapy in improving nasal symptoms such as nasal congestion and rhinorrhea, as well as quality of life in the treatment of (M\/S)AR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000042573","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:00:09Z","timestamp":1748318409000},"page":"e42573","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A clinical study on the combination of bencycloquidium bromide and montelukast in the treatment of moderate to severe allergic rhinitis"],"prefix":"10.1097","volume":"104","author":[{"given":"Shu","family":"Shao","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, The Affiliated People\u2019s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, The Affiliated People\u2019s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, The Affiliated People\u2019s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3764-521X","authenticated-orcid":false,"given":"Junxiang","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, The Affiliated People\u2019s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2024.0530","article-title":"Allergic rhinitis: a review.","volume":"331","author":"Bernstein","year":"2024","journal-title":"JAMA"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.aller.2020.03.010","article-title":"Prevalence of asthma, allergic rhinitis and pollinosis in a city of Brazil: a monitoring study.","volume":"48","author":"Oliveira","year":"2020","journal-title":"Allergol Immunopathol (Madr)"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/alr.23090","article-title":"International consensus statement on allergy and rhinology: allergic rhinitis \u2013 2023.","volume":"13","author":"Wise","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41572-020-00227-0","article-title":"Allergic rhinitis.","volume":"6","author":"Bousquet","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/all.12874","article-title":"An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011.","volume":"71","author":"Wang","year":"2016","journal-title":"Allergy"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0091-6749(99)70370-2","article-title":"Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the european community respiratory health survey.","volume":"104","author":"Leynaert","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"R7-20250527","first-page":"CD003570","article-title":"Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis.","volume":"2003","author":"Taramarcaz","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.anai.2023.07.019","article-title":"Evidence-based use of antihistamines for treatment of allergic conditions.","volume":"131","author":"Linton","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jaci.2017.03.050","article-title":"Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision.","volume":"140","author":"Brozek","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R10-20250527","first-page":"S1","article-title":"Clinical practice guideline: allergic rhinitis.","volume":"152","author":"Seidman","year":"2015","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.3928\/19382359-20181212-01","article-title":"Intranasal steroid therapy for allergic rhinitis.","volume":"48","author":"Seth","year":"2019","journal-title":"Pediatr Ann"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s00405-020-06183-5","article-title":"Bencycloquidium bromide nasal spray is effective and safe for persistent allergic rhinitis: a phase III, multicenter, randomized, double-blinded, placebo-controlled clinical trial.","volume":"277","author":"Jiang","year":"2020","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1111\/all.14586","article-title":"Advances and novel developments in allergic rhinitis.","volume":"75","author":"Meng","year":"2020","journal-title":"Allergy"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/08820139.2019.1634096","article-title":"Local expression of mucosal YKL-40; correlation of YKL-40 with clinical manifestations and immunopathogenesis of moderate\/severe persistent allergic rhinitis patients.","volume":"49","author":"Pirayesh","year":"2020","journal-title":"Immunol Invest"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"618","DOI":"10.4193\/Rhin20.376","article-title":"EUFOREA treatment algorithm for allergic rhinitis.","volume":"58","author":"Hellings","year":"2020","journal-title":"Rhinology"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2332\/allergolint.14-RAI-0768","article-title":"Japanese guideline for allergic rhinitis 2014.","volume":"63","author":"Okubo","year":"2014","journal-title":"Allergol Int"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s40265-020-01406-9","article-title":"Efficacy of montelukast in allergic rhinitis treatment: a systematic review and meta-analysis.","volume":"80","author":"Krishnamoorthy","year":"2020","journal-title":"Drugs"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1046\/j.1398-9995.2003.00261.x","article-title":"Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period.","volume":"58","author":"Van Adelsberg","year":"2003","journal-title":"Allergy"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"E1054","DOI":"10.1002\/lary.28433","article-title":"A randomized trial of comparing a combination of montelukast and budesonide with budesonide in allergic rhinitis.","volume":"131","author":"Chen","year":"2021","journal-title":"Laryngoscope"},{"key":"R20-20250527","first-page":"9570","article-title":"Effect of azelastine hydrochloride combined with montelukast sodium in the treatment of patients with allergic rhinitis.","volume":"13","author":"Zheng","year":"2021","journal-title":"Am J Transl Res"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"1287320","DOI":"10.3389\/fphar.2023.1287320","article-title":"A systematic review and meta-analysis of loratadine combined with montelukast for the treatment of allergic rhinitis.","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.clinthera.2018.04.021","article-title":"A randomized, multicenter, double-blind, phase III study to evaluate the efficacy on allergic rhinitis and safety of a combination therapy of montelukast and levocetirizine in patients with asthma and allergic rhinitis.","volume":"40","author":"Kim","year":"2018","journal-title":"Clin Ther"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/alr.22467","article-title":"Cholinergic neuron-like D-U87 cells promote polarization of allergic rhinitis T-helper 2 cells.","volume":"10","author":"Liu","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/lary.30306","article-title":"Intranasal anticholinergics for treatment of chronic rhinitis: systematic review and meta-analysis.","volume":"133","author":"Pang","year":"2023","journal-title":"Laryngoscope"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jchromb.2009.02.027","article-title":"Solid phase extraction and liquid chromatography\u2013electrospray ionization\u2013mass spectrometry for the determination of bencycloquidium bromide in human plasma.","volume":"877","author":"Zhou","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2011.01.024","article-title":"M(3) muscarinic receptor antagonist bencycloquidium bromide attenuates allergic airway inflammation, hyperresponsiveness and remodeling in mice.","volume":"655","author":"Cao","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"819772","DOI":"10.3389\/fmolb.2022.819772","article-title":"IL-4\/IL-13 axis in allergic rhinitis: elevated serum cytokines levels and inverse association with tight junction molecules expression.","volume":"9","author":"Nur Husna","year":"2022","journal-title":"Front Mol Biosci"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/11599330-000000000-00000","article-title":"Pharmacokinetics, safety and tolerability of bencycloquidium bromide, a novel selective muscarinic M1\/M3 receptor antagonist, after single and multiple intranasal doses in healthy Chinese subjects: an open-label, single-center, first-in-human study.","volume":"12","author":"Sun","year":"2012","journal-title":"Drugs R D"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/21556660.2016.1209507","article-title":"Montelukast in the treatment of perennial allergic rhinitis in paediatric Japanese patients; an open-label clinical trial.","volume":"5","author":"Okubo","year":"2016","journal-title":"J Drug Assess"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jaci.2009.08.011","article-title":"Analysis of behavior-related adverse experiences in clinical trials of montelukast.","volume":"124","author":"Philip","year":"2009","journal-title":"J Allergy Clin Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:00:17Z","timestamp":1748318417000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":30,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042573","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}